Brii Biosciences and Qpex Biopharma Enter into Agreement to Acquire Global Rights for BRII-693
Monday, June 26, 2023
Brii Biosciences has recently made an announcement regarding its strategic agreements with Qpex Biopharma and other third parties.
Under the terms of the agreement, Brii Bio has reached an agreement to acquire exclusive global rights for the development and commercialisation of BRII-693 (also known as QPX9003). Previously, Brii Bio held exclusive rights to this product in Greater China, but with this agreement, it will expand its rights globally.
As part of the agreement, Brii Bio will return its exclusive rights to QPX7728-based products, namely BRII-636 and BRII-672, in Greater China to Qpex. This means that Brii Bio will no longer have exclusive rights to develop and commercialise these products in Greater China.
BRII-693 is a novel synthetic lipopeptide being developed specifically for the treatment of critically ill patients who are suffering from multidrug-resistant (MDR) or extensively drug-resistant (XDR) gram-negative bacterial infections. These infections, particularly caused by carbapenem-resistant strains of Acinetobacter baumannii and Pseudomonas aeruginosa, pose a significant challenge in healthcare settings due to their resistance to commonly used antibiotics.
